Roivant Sciences Ltd. · NASDAQ:ROIV
Roivant Sciences — Q1 2026 Earnings Presentation
22 slides from Roivant Sciences's earnings presentation, Aug 6, 2026
Slide 1: Financial Results and Business Update for the Quarter Ended June 30, 2026
Financial Results and Business Update for the Quarter Ended June 30, 2026 August 6, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks Non-GAAP Financial Information and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than s
Slide 3: Agenda
Agenda Pipeline and Business Updates Financial Update Q&A 3 For investor audiences only
Slide 4: Roivant's Priorities for CY2026
Roivant’s Priorities for CY2026 Convert multiple PoC studies across 3 products into pivotal programs Progress IMVT-1402 Execute on LNP development across litigation multiple pivotal studies Prepare for Add to existing brepocitinib pipeline launch Note: All drugs are investigational and subject to re
Slide 5: Roivant's Priorities for CY2026: Progress Across All Key Goals
Roivant’s Priorities for CY2026: Progress Across All Key Goals First patients enrolled in brepocitinib CS Ph3 study in 3Q following positive Ph2 results in 1Q Received upfront IMVT-1402 showed payment from MRNA; meaningful response filed international rates in D2T RA patients proceedings against PFE
Slide 6: 2H 2026: Catalyst-Rich Period Ahead Across All Pipeline Programs
2H 2026: Catalyst-Rich Period Ahead Across All Pipeline Programs Brepocitinib launch in DM Topline data from brepocitinib Topline data from mosliciguat Ph3 study in NIU Ph2 study in PH-ILD By end of September 2026 2H 2026 2H 2026 IMVT-1402 D2T RA program Topline data from IMVT-1402 updates PoC study
Slide 7: Pipeline and Business Updates
Pipeline and Business Updates
Slide 8: Cutaneous Sarcoidosis: High Urgency to Treat Given Poor Cosmesis and Potential to Cause Irreversible Damage
Cutaneous Sarcoidosis: High Urgency to Treat Given Poor Cosmesis and Potential to Cause Irreversible Damage Unlike many inflammatory skin diseases (e.g., plaque psoriasis, eczema, alopecia areata), untreated cutaneous sarcoidosis can rapidly cause permanent scarring or even cartilaginous destruction
Slide 9: Phase 2 BEACON Data Provide Compelling Evidence of Clinical Benefit
Phase 2 BEACON Data Provide Compelling Evidence of Clinical Benefit Mean CSAMI-A Change from Baseline1 Achievement of CSAMI-A ≥ 10-point Reduction at Week 16 Study Week 0 4 8 12 16 Mean Change from Baseline (± SE) 0 -0.7 -5 MCID 100% -10 73% -15 * -20 14% -22.2 -25 * -22.3 -30 * ** 45 mg vs. Placebo
Slide 10: Cutaneous Sarcoidosis Alone Includes Eligible Population of ~40K Patients
Cutaneous Sarcoidosis Alone Includes Eligible Population of ~40K Patients ~16K have minimal to no activity in other organs Brepocitinib Has the Potential to Become the ~40K have other organ ~24K On-Label Therapy of Choice for All Sarcoidosis CS patients in the US1,2 Patients With Any involvement aff
Slide 11: BEACON+: Phase 3 Study for Brepocitinib in Cutaneous Sarcoidosis
BEACON+: Phase 3 Study for Brepocitinib in Cutaneous Sarcoidosis Enrolling at ~70 sites globally First Patients Enrolled; Topline Data Expected 2028 Week 3:2 Randomization 0 16 Brepocitinib 45 mg QD N=140 Primary Endpoint: CSAMI-A ≥ 50% Adults with active Response CS Placebo Steroid taper: Mandatory
Slide 12: ALPINE: Phase 2b/3 Trial of Brepocitinib in Lichen Planopilaris
ALPINE: Phase 2b/3 Trial of Brepocitinib in Lichen Planopilaris Enrollment Progressing Well Screening Phase 2b (Part 1) 24-week double-blind period + 28-week OLE N = 72 1:1 Randomization • Phase 2b Primary Endpoint: Safety & Tolerability Brepocitinib 45 mg QD (N=36) • Efficacy Endpoints (Week 24): A
Slide 13: Brepocitinib in DM: Well-Positioned to Launch the First Novel Oral Therapy
Brepocitinib in DM: Well-Positioned to Launch the First Novel Oral Therapy Ph3 Study Achieved Statistical DM Remains a Tough Disease; Commercial Launch Plans Significance on All 10 Endpoints High Unmet Need On Track Mean TIS* Expect to launch by end of ~40-70K Addressable ∆CDASI-A* September followi
Slide 14: Brepocitinib Poised For Long-Term Value Across Indications With Continuous Catalyst Flow Expected Through 2028
Brepocitinib Poised For Long-Term Value Across 4 Indications With Continuous Catalyst Flow Expected Through 2028 Cutaneous Sarcoidosis Potential sNDA Approval Lichen Planopilaris Potential sNDA Approval Non-Infectious Uveitis Potential sNDA Approval Non-Infectious Uveitis Cutaneous Sarcoidosis Ph3 T
Slide 15: Moderna Upfront Payment Received and International Proceedings Against Pfizer/BioNTech Initiated
Moderna Upfront Payment Received and International Proceedings Against Pfizer/BioNTech Initiated in July 2026 Moderna $950M $1.3BN $2.25BN Upfront payment Contingent payment Potential aggregate received July 2026 upon favorable Section settlement value1 1498 appellate ruling1 Pfizer/BioNTech Genevan
Slide 16: Financial Update
Financial Update e roivant LLL ZZ ZT IAF + ae eee
Slide 17: Key Financial Items
Key Financial Items Select Income Statement and Non-GAAP Metrics Select Balance Sheet Metrics for the Three Months Ended June 30, 2026 at June 30, 2026 • R&D expense of $202M; adjusted R&D expense of • Cash, cash equivalents, restricted cash and $193M (non-GAAP) marketable securities of $3.9BN as of
Slide 18: Non-GAAP Disclosures
Non-GAAP Disclosures Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited, in thousands) Three Months Ended June 30, Three Months Ended June 30, Note 2026 2025 Note 2026 2025 Net loss $ (290,606) $ (273,911) Research and development expenses $ 202,016 $ 152,919 Adjustments: Adjustments:
Slide 19: Rich Catalyst Calendar
Rich Catalyst Calendar Program Vant Catalyst Expected Timing Roivant pipeline growth New mid/late-stage in-licensing announcements Ongoing Brepocitinib FDA decision on brepocitinib in dermatomyositis 3Q 2026 Mosliciguat Topline data from Phase 2 trial in pulmonary hypertension associated with inters
Slide 20: By the End of CY 2028, Roivant Will Execute on…
By the End of CY 2028, Roivant Will Execute on… 3+ brepocitinib DM NIU 4+ brepocitinib DM NIU Commercial NDA/BLA Launches IMVT-1402 GD Filings* IMVT-1402 GD MG Across 7+ Indications Across 3+ Indications 9+ NIU CS MG CIDP 3+ PH-ILD CLE Pivotal Study POC Study Readouts GD SjD D2T RA Readouts CS brepo
Slide 21: High-Value Pipeline, Delivering Series of Near-Term Catalysts
High-Value Pipeline, Delivering Series of Near-Term Catalysts Phase 1 Phase 2 Registrational Approved Brepocitinib DM PDUFA date 3Q 2026 NIU Topline data 2H 2026 CS Topline data 2028 LPP Phase 2b/3 FPFV 1Q 2026 IMVT-1402 D2T RA Further updates 2H 2026 GD Topline data 2027 MG Topline data 2027 CIDP T
Slide 22: Thank you.
Thank you. roivant